PubMed Health⌕ Search

PubMed · 6521718

Neuroimaging in multiple sclerosis.

Abstract

Conventional CT studies were the first neuroimaging tools shown to be frequently useful in the assessment of patients with multiple sclerosis. The most commonly noted abnormalities are cerebral atrophy, foci of decreased density, and contrast enhancing lesions. Hypodense lesions may represent either recent or remote sites of demyelination and this can be determined in part by the response of these abnormalities to contrast administration and by their evolution with serial CT studies. There is compelling evidence that CT enhancing lesions correspond to sites of active inflammation and demyelination. High-volume delayed CT studies increase the number of CT abnormalities seen, particularly in patients examined at the time of clinical disease activity. These studies appear to be well-tolerated in properly hydrated patients with normal renal function. NMRI studies appear to be the most sensitive way to detect MS lesions and are particularly useful in demonstrating abnormalities in the posterior fossa. Less is known of the pathologic substrate and the evolution of these NMR abnormalities. It appears likely that NMR detected lesions usually do not resolve completely and consequently changes seen with this neuroimaging technique may represent the cumulative effects of past and present disease activity.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J H Noseworthy, D W Paty, G C Ebers. 1984. Neuroimaging in multiple sclerosis.. https://pubmed.ncbi.nlm.nih.gov/6521718/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Multiple sclerosis.

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that commonly leads to inflammatory and atrophic brain pathology, often causing cognitive impairment. MS-associated cognitive impairment was first described over a century ago. However, with the advent of standardized neuropsychological testing and quantitative brain imaging, the frequency, quality, and correlates of cognitive impairment are better understood. Dementia is rare in MS, although it is known to occur in 10 to 25% of patients. Our data suggest a frequency of 22% among clinic attendees. In addition to the cognitive impairments evident in MS dementia, changes in personality and social behavior also occur. For example, some patients develop euphoria sclerotica and marked deficiency in social empathy, conditions that in combination with executive dysfunction cause considerable hardship for patients and caregivers. These neuropsychiatric manifestations of MS dementia are correlated with magnetic resonance imaging indicators of brain atrophy, including ventricle enlargement, neocortical volume, and normalized whole brain volume. Recent developments in pharmacological treatment for disease progression and management of cognitive symptoms hold promise for patients suffering from the degenerative aspects of MS.

Atrophy↗

Inflammation, atrophy, and gastric cancer.

The association between chronic inflammation and cancer is now well established. This association has recently received renewed interest with the recognition that microbial pathogens can be responsible for the chronic inflammation observed in many cancers, particularly those originating in the gastrointestinal system. A prime example is Helicobacter pylori, which infects 50% of the world's population and is now known to be responsible for inducing chronic gastric inflammation that progresses to atrophy, metaplasia, dysplasia, and gastric cancer. This Review provides an overview of recent progress in elucidating the bacterial properties responsible for colonization of the stomach, persistence in the stomach, and triggering of inflammation, as well as the host factors that have a role in determining whether gastritis progresses to gastric cancer. We also discuss how the increased understanding of the relationship between inflammation and gastric cancer still leaves many questions unanswered regarding recommendations for prevention and treatment.

Atrophy↗